company background image
530019 logo

Jubilant Pharmova BSE:530019 Stock Report

Last Price

₹739.35

Market Cap

₹117.6b

7D

1.7%

1Y

91.4%

Updated

17 Jul, 2024

Data

Company Financials

Jubilant Pharmova Limited

BSE:530019 Stock Report

Market Cap: ₹117.6b

530019 Stock Overview

Operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally.

530019 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends3/6

Jubilant Pharmova Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jubilant Pharmova
Historical stock prices
Current Share Price₹739.35
52 Week High₹780.00
52 Week Low₹319.30
Beta1.53
11 Month Change-2.00%
3 Month Change5.37%
1 Year Change91.39%
33 Year Change3.95%
5 Year Change68.19%
Change since IPO3,208.98%

Recent News & Updates

Recent updates

Shareholder Returns

530019IN PharmaceuticalsIN Market
7D1.7%0.8%0.8%
1Y91.4%51.4%45.4%

Return vs Industry: 530019 exceeded the Indian Pharmaceuticals industry which returned 51.4% over the past year.

Return vs Market: 530019 exceeded the Indian Market which returned 45.4% over the past year.

Price Volatility

Is 530019's price volatile compared to industry and market?
530019 volatility
530019 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 530019 has not had significant price volatility in the past 3 months.

Volatility Over Time: 530019's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19785,778Priyavrat Bhartiawww.jubilantpharmova.com

Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.

Jubilant Pharmova Limited Fundamentals Summary

How do Jubilant Pharmova's earnings and revenue compare to its market cap?
530019 fundamental statistics
Market cap₹117.61b
Earnings (TTM)₹771.00m
Revenue (TTM)₹67.03b

152.5x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
530019 income statement (TTM)
Revenue₹67.03b
Cost of Revenue₹21.41b
Gross Profit₹45.62b
Other Expenses₹44.85b
Earnings₹771.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 19, 2024

Earnings per share (EPS)4.85
Gross Margin68.06%
Net Profit Margin1.15%
Debt/Equity Ratio63.0%

How did 530019 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

103%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.